European Medicines Agency Accepts Veloxis Pharmaceuticals A/S (VELO)' Marketing Authorization Application (MAA) for LCP-Tacro for Treatment of Kidney Transplant Patients
5/22/2013 9:38:02 AM
More...
|
Veloxis Pharmaceuticals A/S (VELO) Release: Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro™ to Improve Tacrolimus-Induced Tremors
5/20/2013 10:12:49 AM
More...
|
Veloxis Pharmaceuticals A/S (VELO) Release: Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors
5/20/2013 9:56:48 AM
More...
|
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results for the First Three Months of 2013
5/16/2013 6:17:00 AM
More...
|
Veloxis Pharmaceuticals A/S (VELO) to Host Conference Call Announcing Interim Report for First Quarter 2013 – Results From 1 January to 31 March, 2013
5/7/2013 9:47:54 AM
More...
|
Veloxis Pharmaceuticals A/S (VELO) Announces Submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) for LCP-Tacro™ for Treatment of Kidney Transplant Patients
4/29/2013 10:33:21 AM
More...
|
Veloxis Pharmaceuticals A/S (VELO) - Passing of Ordinary General Meeting
4/17/2013 11:23:10 AM
More...
|
Veloxis Pharmaceuticals A/S (VELO) Publishes Annual Report 2012
3/6/2013 9:42:55 AM
More...
|
Veloxis Pharmaceuticals A/S (VELO) to Host Conference Call Announcing Annual report 2012
2/27/2013 1:25:27 PM
More...
|
Veloxis Pharmaceuticals A/S (VELO) Establishes a New Warrant Programme
1/24/2013 9:30:31 AM
More...
|
|